Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone

Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.

Detalles Bibliográficos
Autores principales: Ghanekar, Shaila D, Miller, Wai Wai, Meyer, Colin J, Fenelon, Kevin J, Lacdao, Alvin, Zesiewicz, Theresa A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800542/
https://www.ncbi.nlm.nih.gov/pubmed/31686946
http://dx.doi.org/10.2147/DNND.S180027
_version_ 1783460466488508416
author Ghanekar, Shaila D
Miller, Wai Wai
Meyer, Colin J
Fenelon, Kevin J
Lacdao, Alvin
Zesiewicz, Theresa A
author_facet Ghanekar, Shaila D
Miller, Wai Wai
Meyer, Colin J
Fenelon, Kevin J
Lacdao, Alvin
Zesiewicz, Theresa A
author_sort Ghanekar, Shaila D
collection PubMed
description Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA.
format Online
Article
Text
id pubmed-6800542
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68005422019-11-04 Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone Ghanekar, Shaila D Miller, Wai Wai Meyer, Colin J Fenelon, Kevin J Lacdao, Alvin Zesiewicz, Theresa A Degener Neurol Neuromuscul Dis Review Friedreich’s Ataxia (FRDA) is a devastating and progressive ataxia, marked by mitochondrial dysfunction and oxidative stress. Nrf2 activators such as omaveloxolone (Omav) modulate antioxidative mechanisms, and thus may be viable therapeutic agents in FRDA. Dove 2019-10-15 /pmc/articles/PMC6800542/ /pubmed/31686946 http://dx.doi.org/10.2147/DNND.S180027 Text en © 2019 Ghanekar et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Ghanekar, Shaila D
Miller, Wai Wai
Meyer, Colin J
Fenelon, Kevin J
Lacdao, Alvin
Zesiewicz, Theresa A
Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
title Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
title_full Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
title_fullStr Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
title_full_unstemmed Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
title_short Orphan Drugs In Development For The Treatment Of Friedreich’s Ataxia: Focus On Omaveloxolone
title_sort orphan drugs in development for the treatment of friedreich’s ataxia: focus on omaveloxolone
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800542/
https://www.ncbi.nlm.nih.gov/pubmed/31686946
http://dx.doi.org/10.2147/DNND.S180027
work_keys_str_mv AT ghanekarshailad orphandrugsindevelopmentforthetreatmentoffriedreichsataxiafocusonomaveloxolone
AT millerwaiwai orphandrugsindevelopmentforthetreatmentoffriedreichsataxiafocusonomaveloxolone
AT meyercolinj orphandrugsindevelopmentforthetreatmentoffriedreichsataxiafocusonomaveloxolone
AT fenelonkevinj orphandrugsindevelopmentforthetreatmentoffriedreichsataxiafocusonomaveloxolone
AT lacdaoalvin orphandrugsindevelopmentforthetreatmentoffriedreichsataxiafocusonomaveloxolone
AT zesiewicztheresaa orphandrugsindevelopmentforthetreatmentoffriedreichsataxiafocusonomaveloxolone

Ejemplares similares